ArticleBreast cancer research and treatment2009
Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors.
Article in Breast cancer research and treatment, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 56 citations in OpenAlex.
- Prognostic and clinicopathologic significance of FGFR mRNA and protein overexpression in colorectal cancer: a systematic review and meta-analysis.Translational cancer research · 2026Article
- Stathmin expression associates with vascular and immune responses in aggressive breast cancer subgroups.Scientific reports · 2020Article
- Association between hereditary predisposition to common cancers and congenital multimalformations.Congenital anomalies · 2020Article
- Differential Profile of BRCA1 vs. BRCA2 Mutated Families: A Characterization of the Main Differences and Similarities in Patients.Asian Pacific journal of cancer prevention : APJCP · 2019Article
- Article
- FGF7/FGFR2 signal promotes invasion and migration in human gastric cancer through upregulation of thrombospondin-1.International journal of oncology · 2017Article
- Fibroblast Growth Factor Receptor 2 Signaling in Breast Cancer.International journal of biological sciences · 2017Review
- Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?Oncotarget · 2015Review
- Impact of Prophylactic Mastectomy in BRCA1/2 Mutation Carriers.Breast care (Basel, Switzerland) · 2014Review
- Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells.Oncogene · 2014Article
- Hereditary breast cancer: clinical, pathological and molecular characteristics.Breast cancer : basic and clinical research · 2014Review
- The notch ligand JAGGED1 as a target for anti-tumor therapy.Frontiers in oncology · 2014Review
- BRCA1 is a key regulator of breast differentiation through activation of Notch signalling with implications for anti-endocrine treatment of breast cancers.Nucleic acids research · 2013Article
- The complex genetic landscape of familial breast cancer.Human genetics · 2013Review
- Correlation of Notch1, pAKT and nuclear NF-κB expression in triple negative breast cancer.American journal of cancer research · 2013Article
- HIF-1α overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers.PloS one · 2013Article
- Differential expression of growth factor receptors and membrane-bound tumor markers for imaging in male and female breast cancer.PloS one · 2013Article
- A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS).Human mutation · 2012Review
- Pathology of hereditary breast cancer.Cellular oncology (Dordrecht, Netherlands) · 2011Review
- Phenotype-genotype correlation in familial breast cancer.Journal of mammary gland biology and neoplasia · 2011Review
Corrections and comments
- Erratum issuedReedijk, Michael [added]; Egan, Sean E [added]
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBRCA1- and BRCA2-associated tumors appear to have distinct molecular signatures. BRCA1-associated tumors are predominantly basal-like cancers, whereas BRCA2-associated tumors have a predominant luminal-like phenotype. These two molecular signatures reflect in part the two cell types found in the terminal duct lobular unit of the breast. To elucidate novel genes involved in these two spectra of breast tumorigenesis we performed global gene expression analysis on breast tumors from germline BRCA1 and BRCA2 mutation carriers. METHODOLOGY: Breast tumor RNAs from 7 BRCA1 and 6 BRCA2 mutation carriers were profiled using UHN human 19K cDNA microarrays. Supervised univariate analyses were conducted to identify genes differentially expressed between BRCA1 and BRCA2-associated tumors. Selected discriminatory genes were validated using real time reverse transcription polymerase chain reaction in the tumor RNAs, and/or by immunohistochemistry (IHC) or by in situ hybridization (ISH) on tissue microarrays (TMAs) containing an independent set of 58 BRCA1 and 64 BRCA2-associated tumors.
resultsGenes more highly expressed in BRCA1-associated tumors included stathmin, osteopontin, TGFbeta2 and Jagged 1 in addition to genes previously identified as characteristic of basal-like breast cancers. BRCA2-associated cancers were characterized by the higher relative expression of FGF1 and FGFR2. FGFR2 protein was also more highly expressed in BRCA2-associated cancers (P = 0.004). SIGNIFICANCE: BRCA1-associated tumours demonstrated increased expression of component genes of the Notch and TGFbeta pathways whereas the higher expression of FGFR2 and FGF1 in BRCA2-associated cancers suggests the existence of an autocrine stimulatory loop.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.